-
2025-523076-23-00
4
Adenomyosis
-
2025-523539-20-00
4
Low Grade Upper Tract Urothelial Carcinoma
-
2025-523674-16-00
5
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2025-523675-39-00
5
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2025-524005-32-00
4
Rheumatoid arthritis
-
2025-524640-35-00
4
Ulcerative colitis (Inflammatory Bowel Disease)
-
2025-524775-23-00
2
No therapeutic indication in the current trial with healthy volunteers
-
2026-525269-34-00
3
The intended indication is for the treatment of major depressive disor
-
2025-521038-27-00
5
2026-06-23
Immune system diseases
-
2025-522406-20-00
9
2026-06-15
Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
-
2025-523576-23-00
5
2026-06-12
Unresectable Stage III non-small cell lung cancer without progression
-
2025-523586-18-00
5
2026-06-11
Non-Small Cell Lung Cancer
-
2025-521950-41-00
5
2026-06-05
severe uncontrolled asthma
-
2025-523488-39-00
4
2026-06-02
Systemic lupus erythematosus
-
2024-519994-20-00
5
2026-06-01
Agitation Associated with Alzheimer’s Disease
-
2024-520446-31-00
5
2026-05-27
Participants with overweight or obesity, and type 2 diabetes
-
2025-522001-38-00
4
2026-05-27
Crohn’s Disease
-
2025-524001-33-00
4
2026-05-22
Graves’ Disease
-
2025-522511-42-00
4
2026-05-19
Crohn's disease
-
2025-521711-39-00
5
2026-05-17
Lewy body Dementia psychosis (LBDP)
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-511593-70-00
5
2026-04-27
Polyarticular-course juvenile idiopathic arthritis
-
2024-519830-22-00
5
2026-04-27
Heart failure due to systemic left ventricular systolic dysfunction
-
2025-522878-36-00
5
2026-04-20
Chronic Spontaneous Urticaria